No patient left behind : The promise of immune priming with epigenetic agents

Show full item record



Permalink

http://hdl.handle.net/10138/228981

Citation

Carter , C A , Oronsky , B T , Roswarski , J , Oronsky , A L , Oronsky , N , Scicinski , J , Lybeck , H , Kim , M M , Lybeck , M & Reid , T R 2017 , ' No patient left behind : The promise of immune priming with epigenetic agents ' , OncoImmunology , vol. 6 , no. 10 , 1315486 . https://doi.org/10.1080/2162402X.2017.1315486

Title: No patient left behind : The promise of immune priming with epigenetic agents
Author: Carter, Corey A.; Oronsky, Bryan T.; Roswarski, Joseph; Oronsky, Arnold L.; Oronsky, Neil; Scicinski, Jan; Lybeck, Harry; Kim, Michelle M.; Lybeck, Michelle; Reid, Tony R.
Contributor: University of Helsinki, Department of Physiology
Date: 2017
Language: eng
Number of pages: 13
Belongs to series: OncoImmunology
ISSN: 2162-402X
URI: http://hdl.handle.net/10138/228981
Abstract: Checkpoint inhibitors, monoclonal antibodies that inhibit PD-1 or CTLA-4, have revolutionized the treatment of multiple cancers. Despite the enthusiasm for the clinical successes of checkpoint inhibitors, and immunotherapy, in general, only a minority of patients with specific tumor types actually benefit from treatment. Emerging evidence implicates epigenetic alterations as a mechanism of clinical resistance to immunotherapy. This review presents evidence for that association, summarizes the epi-based mechanisms by which tumors evade immunogenic cell death, discusses epigenetic modulation as a component of an integrated strategy to boost anticancer T cell effector function in relation to a tumor immunosuppression cycle and, finally, makes the case that the success of this no-patient-left-behind strategy critically depends on the toxicity profile of the epigenetic agent(s).
Subject: Immunotherapy
immunosuppression
immunogenic cell death
epigenetic modulation
checkpoint inhibitors
resistance
REGULATORY T-CELLS
TUMOR-INFILTRATING LYMPHOCYTES
COLON-CANCER-CELLS
CLASS-I ANTIGENS
MHC CLASS-I
DNA METHYLATION
GENE-EXPRESSION
NECROSIS-FACTOR
LUNG-CANCER
FAS LIGAND
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
2162402X.2017.pdf 1.725Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record